triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART trial 48 week virological response to a triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART trial

ABSTRACT Introduction: Introduction: There are few viral load (VL) data on ZDV+3TC+TDF (tenofovir DF) as first-line therapy. We therefore evaluated VL response through 48 weeks, and emergence of genotypic mutations in those with VL>1000 c/ml at 24 weeks, in naive adults initiating ART in the DART trial.